{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T08:55:19Z","timestamp":1787993719995,"version":"build-2784847793"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24420-x","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T14:46:14Z","timestamp":1763477174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Establishment of novel cholangiocarcinoma cell lines with ARID1A deficiency and preclinical validation of synthetic lethality therapies"],"prefix":"10.1038","volume":"15","author":[{"given":"Sunisa","family":"Prasopporn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunya","family":"Sittithumcharee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jantappapa","family":"Chanthercrob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somchai","family":"Limsrichamrern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arada","family":"Hirankitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimkanya","family":"More-Krong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakda","family":"Sathirareuangchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amphun","family":"Chaiboonchoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somponnat","family":"Sampattavanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwanon","family":"Jirawatnotai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"24420_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales, J. M. et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 17, 557\u2013588. https:\/\/doi.org\/10.1038\/s41575-020-0310-z (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"24420_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.850732","volume":"12","author":"Q Zheng","year":"2022","unstructured":"Zheng, Q., Zhang, B., Li, C. & Zhang, X. Overcome drug resistance in cholangiocarcinoma: New insight into mechanisms and refining the preclinical experiment models. Front Oncol. 12, 850732. https:\/\/doi.org\/10.3389\/fonc.2022.850732 (2022).","journal-title":"Front Oncol."},{"key":"24420_CR3","doi-asserted-by":"publisher","first-page":"1142690","DOI":"10.3389\/fimmu.2023.1142690","volume":"14","author":"J Du","year":"2023","unstructured":"Du, J., Lv, X., Zhang, Z., Huang, Z. & Zhang, E. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma. Front Immunol. 14, 1142690. https:\/\/doi.org\/10.3389\/fimmu.2023.1142690 (2023).","journal-title":"Front Immunol."},{"key":"24420_CR4","doi-asserted-by":"publisher","first-page":"1136248","DOI":"10.3389\/fonc.2023.1136248","volume":"13","author":"B Fontana","year":"2023","unstructured":"Fontana, B. et al. ARID1A in cancer: Friend or foe?. Front Oncol. 13, 1136248. https:\/\/doi.org\/10.3389\/fonc.2023.1136248 (2023).","journal-title":"Front Oncol."},{"key":"24420_CR5","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen, J. et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 5, 752\u2013767. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0849 (2015).","journal-title":"Cancer Discov."},{"key":"24420_CR6","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1158\/1078-0432.CCR-18-4222","volume":"25","author":"Y Park","year":"2019","unstructured":"Park, Y. et al. Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy. Clin. Cancer Res. 25, 5584\u20135594. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-4222 (2019).","journal-title":"Clin. Cancer Res."},{"key":"24420_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccell.2018.12.009","volume":"35","author":"H Ogiwara","year":"2019","unstructured":"Ogiwara, H. et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell 35, 177\u2013190. https:\/\/doi.org\/10.1016\/j.ccell.2018.12.009 (2019).","journal-title":"Cancer Cell"},{"key":"24420_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nm.3799","volume":"21","author":"BG Bitler","year":"2015","unstructured":"Bitler, B. G. et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat. Med. 21, 231\u2013238. https:\/\/doi.org\/10.1038\/nm.3799 (2015).","journal-title":"Nat. Med."},{"key":"24420_CR9","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/modpathol.2013.96","volume":"26","author":"T Bosse","year":"2013","unstructured":"Bosse, T. et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod. Pathol. 26, 1525\u20131535. https:\/\/doi.org\/10.1038\/modpathol.2013.96 (2013).","journal-title":"Mod. Pathol."},{"key":"24420_CR10","doi-asserted-by":"publisher","first-page":"4931","DOI":"10.2147\/CMAR.S207329","volume":"11","author":"Y Yang","year":"2019","unstructured":"Yang, Y. et al. Loss of ARID1A promotes proliferation, migration and invasion via the Akt signaling pathway in NPC. Cancer Manag. Res. 11, 4931\u20134946. https:\/\/doi.org\/10.2147\/CMAR.S207329 (2019).","journal-title":"Cancer Manag. Res."},{"key":"24420_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.molmed.2023.04.005","volume":"29","author":"F Jin","year":"2023","unstructured":"Jin, F. et al. ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications. Trends Mol. Med. 29, 646\u2013658. https:\/\/doi.org\/10.1016\/j.molmed.2023.04.005 (2023).","journal-title":"Trends Mol. Med."},{"key":"24420_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s10020-022-00469-6","volume":"28","author":"S Zhao","year":"2022","unstructured":"Zhao, S. et al. Roles of ARID1A variations in colorectal cancer: A collaborative review. Mol. Med. 28, 42. https:\/\/doi.org\/10.1186\/s10020-022-00469-6 (2022).","journal-title":"Mol. Med."},{"key":"24420_CR13","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1038\/ng.2806","volume":"45","author":"W Chan-On","year":"2013","unstructured":"Chan-On, W. et al. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat. Genet. 45, 1474\u20131478. https:\/\/doi.org\/10.1038\/ng.2806 (2013).","journal-title":"Nat. Genet."},{"key":"24420_CR14","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1038\/ncomms6696","volume":"5","author":"S Zou","year":"2014","unstructured":"Zou, S. et al. Mutational landscape of intrahepatic cholangiocarcinoma. Nat. Commun. 5, 5696. https:\/\/doi.org\/10.1038\/ncomms6696 (2014).","journal-title":"Nat. Commun."},{"key":"24420_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ccell.2017.05.009","volume":"32","author":"J Chaisaingmongkol","year":"2017","unstructured":"Chaisaingmongkol, J. et al. Common molecular subtypes among asian hepatocellular carcinoma and cholangiocarcinoma. Cancer Cell 32, 57\u201370. https:\/\/doi.org\/10.1016\/j.ccell.2017.05.009 (2017).","journal-title":"Cancer Cell"},{"key":"24420_CR16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul, A. et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 7, 1116\u20131135. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0368 (2017).","journal-title":"Cancer Discov."},{"key":"24420_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.febslet.2010.11.024","volume":"585","author":"SM Nijman","year":"2011","unstructured":"Nijman, S. M. Synthetic lethality: General principles, utility and detection using genetic screens in human cells. FEBS Lett. 585, 1\u20136. https:\/\/doi.org\/10.1016\/j.febslet.2010.11.024 (2011).","journal-title":"FEBS Lett."},{"key":"24420_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41392-020-00358-6","volume":"5","author":"S Li","year":"2020","unstructured":"Li, S. et al. Development of synthetic lethality in cancer: molecular and cellular classification. Signal Transduct Target Ther. 5, 241. https:\/\/doi.org\/10.1038\/s41392-020-00358-6 (2020).","journal-title":"Signal Transduct Target Ther."},{"key":"24420_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155899","author":"H Rehman","year":"2022","unstructured":"Rehman, H. et al. ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.155899 (2022).","journal-title":"JCI Insight"},{"key":"24420_CR20","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.18632\/oncotarget.2092","volume":"5","author":"EP Samartzis","year":"2014","unstructured":"Samartzis, E. P. et al. Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 5, 5295\u20135303. https:\/\/doi.org\/10.18632\/oncotarget.2092 (2014).","journal-title":"Oncotarget"},{"key":"24420_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081769","author":"K Takahashi","year":"2021","unstructured":"Takahashi, K., Takenaka, M., Okamoto, A., Bowtell, D. D. L. & Kohno, T. Treatment strategies for ARID1A-deficient ovarian clear cell carcinoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13081769 (2021).","journal-title":"Cancers (Basel)."},{"key":"24420_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ajhg.2017.01.004","volume":"100","author":"Q Li","year":"2017","unstructured":"Li, Q. & Wang, K. InterVar: Clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am. J. Hum. Genet. 100, 267\u2013280. https:\/\/doi.org\/10.1016\/j.ajhg.2017.01.004 (2017).","journal-title":"Am. J. Hum. Genet."},{"key":"24420_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nature19057","volume":"536","author":"M Lek","year":"2016","unstructured":"Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285\u2013291. https:\/\/doi.org\/10.1038\/nature19057 (2016).","journal-title":"Nature"},{"key":"24420_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424. https:\/\/doi.org\/10.1038\/gim.2015.30 (2015).","journal-title":"Genet. Med."},{"key":"24420_CR25","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate, J. G. et al. COSMIC: The catalogue of somatic mutations in cancer. Nucleic Acids Res. 47, D941\u2013D947. https:\/\/doi.org\/10.1093\/nar\/gky1015 (2019).","journal-title":"Nucleic Acids Res."},{"key":"24420_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/biostatistics\/kxj037","volume":"8","author":"WE Johnson","year":"2007","unstructured":"Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118\u2013127. https:\/\/doi.org\/10.1093\/biostatistics\/kxj037 (2007).","journal-title":"Biostatistics"},{"key":"24420_CR27","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.2","volume":"4","author":"C Soneson","year":"2015","unstructured":"Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4, 1521. https:\/\/doi.org\/10.12688\/f1000research.7563.2 (2015).","journal-title":"F1000Res"},{"key":"24420_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8 (2014).","journal-title":"Genome Biol."},{"key":"24420_CR29","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb) 2, 100141. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141 (2021).","journal-title":"Innovation (Camb)"},{"key":"24420_CR30","volume-title":"Univariate Discrete Distributions","author":"NL Johnson","year":"1994","unstructured":"Johnson, N. L., Kotz, S. & Kemp, A. W. Univariate Discrete Distributions 2nd edn. (Wiley, London, 1994).","edition":"2"},{"key":"24420_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/539748","volume":"2011","author":"A Ono","year":"2011","unstructured":"Ono, A. et al. Comparative study of human hematopoietic cell engraftment into BALB\/c and C57BL\/6 strain of rag-2\/jak3 double-deficient mice. J. Biomed. Biotechnol. 2011, 539748. https:\/\/doi.org\/10.1155\/2011\/539748 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"24420_CR32","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/nmeth.3853","volume":"13","author":"M Hafner","year":"2016","unstructured":"Hafner, M., Niepel, M., Chung, M. & Sorger, P. K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat. Methods 13, 521\u2013527. https:\/\/doi.org\/10.1038\/nmeth.3853 (2016).","journal-title":"Nat. Methods"},{"key":"24420_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050496","author":"K Vaeteewoottacharn","year":"2019","unstructured":"Vaeteewoottacharn, K. et al. Establishment of highly transplantable cholangiocarcinoma cell lines from a patient-derived xenograft mouse model. Cells https:\/\/doi.org\/10.3390\/cells8050496 (2019).","journal-title":"Cells"},{"key":"24420_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2147\/CMAR.S156837","volume":"10","author":"W Guo","year":"2018","unstructured":"Guo, W., Tan, H. Y., Wang, N., Wang, X. & Feng, Y. Deciphering hepatocellular carcinoma through metabolomics: From biomarker discovery to therapy evaluation. Cancer Manag. Res. 10, 715\u2013734. https:\/\/doi.org\/10.2147\/CMAR.S156837 (2018).","journal-title":"Cancer Manag. Res."},{"key":"24420_CR35","doi-asserted-by":"publisher","first-page":"1124147","DOI":"10.3389\/fonc.2023.1124147","volume":"13","author":"VA Yakovlev","year":"2023","unstructured":"Yakovlev, V. A., Sullivan, S. A., Fields, E. C. & Temkin, S. M. PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K\/Akt1-dependent mechanism of synthetic lethality. Front Oncol. 13, 1124147. https:\/\/doi.org\/10.3389\/fonc.2023.1124147 (2023).","journal-title":"Front Oncol."},{"key":"24420_CR36","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jhep.2017.10.028","volume":"68","author":"C Hu","year":"2018","unstructured":"Hu, C. et al. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma. J. Hepatol. 68, 465\u2013475. https:\/\/doi.org\/10.1016\/j.jhep.2017.10.028 (2018).","journal-title":"J. Hepatol."},{"key":"24420_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.999626","volume":"12","author":"S Xu","year":"2022","unstructured":"Xu, S. et al. Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy. Front Oncol. 12, 999626. https:\/\/doi.org\/10.3389\/fonc.2022.999626 (2022).","journal-title":"Front Oncol."},{"key":"24420_CR38","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.12750","volume":"10","author":"S Tessiri","year":"2022","unstructured":"Tessiri, S. et al. Therapeutic targeting of ARID1A and PI3K\/AKT pathway alterations in cholangiocarcinoma. PeerJ 10, e12750. https:\/\/doi.org\/10.7717\/peerj.12750 (2022).","journal-title":"PeerJ"},{"key":"24420_CR39","doi-asserted-by":"publisher","first-page":"105182","DOI":"10.1016\/j.isci.2022.105182","volume":"25","author":"S Jamnongsong","year":"2022","unstructured":"Jamnongsong, S. et al. Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma. iScience 25, 105182. https:\/\/doi.org\/10.1016\/j.isci.2022.105182 (2022).","journal-title":"iScience"},{"key":"24420_CR40","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.10464","volume":"8","author":"A Namjan","year":"2020","unstructured":"Namjan, A., Techasen, A., Loilome, W., Sa-Ngaimwibool, P. & Jusakul, A. ARID1A alterations and their clinical significance in cholangiocarcinoma. PeerJ 8, e10464. https:\/\/doi.org\/10.7717\/peerj.10464 (2020).","journal-title":"PeerJ"},{"key":"24420_CR41","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand, K. C. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363, 1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1008433 (2010).","journal-title":"N. Engl. J. Med."},{"key":"24420_CR42","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/0008-5472.CAN-18-2446","volume":"80","author":"Q Luo","year":"2020","unstructured":"Luo, Q. et al. ARID1A hypermethylation disrupts transcriptional homeostasis to promote squamous cell carcinoma progression. Cancer Res. 80, 406\u2013417. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-2446 (2020).","journal-title":"Cancer Res."},{"key":"24420_CR43","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/MOG.0000000000000611","volume":"36","author":"C Louis","year":"2020","unstructured":"Louis, C., Papoutsoglou, P. & Coulouarn, C. Molecular classification of cholangiocarcinoma. Curr. Opin. Gastroenterol. 36, 57\u201362. https:\/\/doi.org\/10.1097\/MOG.0000000000000611 (2020).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"24420_CR44","doi-asserted-by":"publisher","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","volume":"19","author":"F Farshidfar","year":"2017","unstructured":"Farshidfar, F. et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 19, 2878\u20132880. https:\/\/doi.org\/10.1016\/j.celrep.2017.06.008 (2017).","journal-title":"Cell Rep."},{"key":"24420_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053931","volume":"8","author":"X Zhang","year":"2013","unstructured":"Zhang, X. et al. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers. PLoS ONE 8, e53931. https:\/\/doi.org\/10.1371\/journal.pone.0053931 (2013).","journal-title":"PLoS ONE"},{"key":"24420_CR46","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s12885-020-6706-x","volume":"20","author":"M Erfani","year":"2020","unstructured":"Erfani, M. et al. Altered ARID1A expression in colorectal cancer. BMC Cancer 20, 350. https:\/\/doi.org\/10.1186\/s12885-020-6706-x (2020).","journal-title":"BMC Cancer"},{"key":"24420_CR47","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1158\/0008-5472.CAN-21-0206","volume":"81","author":"S Zhang","year":"2021","unstructured":"Zhang, S. et al. mTORC1 promotes ARID1A degradation and oncogenic chromatin remodeling in hepatocellular carcinoma. Cancer Res. 81, 5652\u20135665. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0206 (2021).","journal-title":"Cancer Res."},{"key":"24420_CR48","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.celrep.2019.12.017","volume":"30","author":"Q Luo","year":"2020","unstructured":"Luo, Q. et al. TRIM32\/USP11 balances ARID1A stability and the oncogenic\/tumor-suppressive status of squamous cell carcinoma. Cell Rep. 30, 98\u2013111. https:\/\/doi.org\/10.1016\/j.celrep.2019.12.017 (2020).","journal-title":"Cell Rep."},{"key":"24420_CR49","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.1021\/pr500470h","volume":"13","author":"A Kimura","year":"2014","unstructured":"Kimura, A., Arakawa, N. & Hirano, H. Mass spectrometric analysis of the phosphorylation levels of the SWI\/SNF chromatin remodeling\/tumor suppressor proteins ARID1A and Brg1 in ovarian clear cell adenocarcinoma cell lines. J. Proteome Res. 13, 4959\u20134969. https:\/\/doi.org\/10.1021\/pr500470h (2014).","journal-title":"J. Proteome Res."},{"key":"24420_CR50","doi-asserted-by":"publisher","first-page":"9236","DOI":"10.1158\/0008-5472.CAN-05-1225","volume":"65","author":"NG Nagl Jr","year":"2005","unstructured":"Nagl, N. G. Jr. et al. The p270 (ARID1A\/SMARCF1) subunit of mammalian SWI\/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res. 65, 9236\u20139244. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1225 (2005).","journal-title":"Cancer Res."},{"key":"24420_CR51","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1158\/0008-5472.CAN-05-3427","volume":"66","author":"NG Nagl Jr","year":"2006","unstructured":"Nagl, N. G. Jr., Zweitzig, D. R., Thimmapaya, B., Beck, G. R. Jr. & Moran, E. The c-myc gene is a direct target of mammalian SWI\/SNF-related complexes during differentiation-associated cell cycle arrest. Cancer Res. 66, 1289\u20131293. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3427 (2006).","journal-title":"Cancer Res."},{"key":"24420_CR52","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10120-023-01373-6","volume":"26","author":"T Sato","year":"2023","unstructured":"Sato, T. et al. ARID1A deficiency is targetable by AKT inhibitors in HER2-negative gastric cancer. Gastric Cancer 26, 379\u2013392. https:\/\/doi.org\/10.1007\/s10120-023-01373-6 (2023).","journal-title":"Gastric Cancer"},{"key":"24420_CR53","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1158\/0008-5472.CAN-22-3646","volume":"83","author":"ZC Yu","year":"2023","unstructured":"Yu, Z. C. et al. Temozolomide sensitizes ARID1A-mutated cancers to PARP inhibitors. Cancer Res. 83, 2750\u20132762. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-3646 (2023).","journal-title":"Cancer Res."},{"key":"24420_CR54","doi-asserted-by":"publisher","first-page":"8621","DOI":"10.1038\/s41598-025-93192-1","volume":"15","author":"R Jaidee","year":"2025","unstructured":"Jaidee, R. et al. Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization. Sci. Rep. 15, 8621. https:\/\/doi.org\/10.1038\/s41598-025-93192-1 (2025).","journal-title":"Sci. Rep."},{"key":"24420_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118273","volume":"189","author":"R Jaidee","year":"2025","unstructured":"Jaidee, R. et al. Synergistic suppression of cholangiocarcinoma cells via DNA damage response and cell cycle arrest by dual targeting PARP and ATM in DNA damage repair pathway. Biomed. Pharmacother. 189, 118273. https:\/\/doi.org\/10.1016\/j.biopha.2025.118273 (2025).","journal-title":"Biomed. Pharmacother."},{"key":"24420_CR56","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40661-017-0052-y","volume":"4","author":"JK Alldredge","year":"2017","unstructured":"Alldredge, J. K. & Eskander, R. N. EZH2 inhibition in ARID1A mutated clear cell and endometrioid ovarian and endometrioid endometrial cancers. Gynecol. Oncol. Res. Pract. 4, 17. https:\/\/doi.org\/10.1186\/s40661-017-0052-y (2017).","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"24420_CR57","doi-asserted-by":"publisher","first-page":"13837","DOI":"10.1038\/ncomms13837","volume":"7","author":"CT Williamson","year":"2016","unstructured":"Williamson, C. T. et al. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nat. Commun. 7, 13837. https:\/\/doi.org\/10.1038\/ncomms13837 (2016).","journal-title":"Nat. Commun."},{"key":"24420_CR58","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ncb3582","volume":"19","author":"BG Bitler","year":"2017","unstructured":"Bitler, B. G. et al. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat. Cell Biol. 19, 962\u2013973. https:\/\/doi.org\/10.1038\/ncb3582 (2017).","journal-title":"Nat. Cell Biol."},{"key":"24420_CR59","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1007\/s12672-024-01433-y","volume":"15","author":"RS Qin","year":"2024","unstructured":"Qin, R. S. et al. AURKA inhibition shows promise as a therapeutic strategy for ARID1A-mutant colorectal cancer. Discov. Oncol. 15, 556. https:\/\/doi.org\/10.1007\/s12672-024-01433-y (2024).","journal-title":"Discov. Oncol."},{"key":"24420_CR60","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1535-7163.MCT-15-0554","volume":"15","author":"RE Miller","year":"2016","unstructured":"Miller, R. E. et al. Synthetic lethal targeting of ARID1A-mutant ovarian clear cell tumors with dasatinib. Mol. Cancer Ther. 15, 1472\u20131484. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0554 (2016).","journal-title":"Mol. Cancer Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24420-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24420-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24420-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T14:46:15Z","timestamp":1763477175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24420-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24420"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24420-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"31 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40619"}}